Whole-Body Imaging of Multiple Myeloma: Diagnostic Criteria

Filho, Alípio Gomes Ormond; Carneiro, Bruno Cerretti; Pastore, Daniel; Silva, Igor P.; Yamashita, Sâmia R.; Consolo, Flávio D.; Hungria, Vânia; Sandes, Alex Freire; Rizzatti, Edgar Gil; Nico, Marcelo Astolfi Caetano

doi:10.1148/rg.2019180096.pres

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is the scan with arms over the head (to reduce beam hardening artifacts on vertebrae if arms are placed on the side of the body). 21 Even one focal lesion of size greater than 5 mm is sufficient for diagnosis. 22…”

Section: Imaging Guidelinesmentioning

confidence: 99%

Imaging Recommendations for Diagnosis, Staging, and Management of Hematological Malignancies

Guha

2023

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

The NIC defines hematological cancers as those that begin in blood forming tissues such as bone marrow or cells of the immune system and these broadly include three groups: leukemias, lymphomas, and myelomas. The role of imaging is also fundamentally different between the three main groups of hematological malignancies. While imaging is the main tool for staging as well as treatment response assessment in lymphoma, it represents one of several key criteria for the diagnosis and follow-up of myeloma; whereas in leukemia, imaging has a role to play in the detection and management of treatment-related complications which is a crucial part of post-transplant treatment.

show abstract

Section: Imaging Guidelinesmentioning

confidence: 99%

Imaging Recommendations for Diagnosis, Staging, and Management of Hematological Malignancies

Guha

2023

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

show abstract

“…It can be proceeded by a premalignant condition called monoclonal gammopathy of undetermined significance (MGUS) that may progress into MM following changes in the bone marrow microenvironment, such as induction of angiogenesis 2 . Active MM can present with a variety of clinical features that can include hypercalcaemia, renal insufficiency, anemia, and bone lesions 3 . Bone lesions, which may result in severe osteopenia and pathologic bone fractures, are considered a hallmark of multiple myeloma as they are present in app.…”

Section: Introductionmentioning

confidence: 99%

Association of RANK and RANKL gene polymorphism with survival and calcium levels in multiple myeloma

Łacina

Butrym

Humiński

et al. 2020

Molecular Carcinogenesis

View full text Add to dashboard Cite

Multiple myeloma (MM) is a heterogeneous bone marrow cancer characterized by proliferation of malignant plasma cells in the bone marrow. One of its major symptoms are hypercalcaemia and bone lesions, which may result in pathologic bone fractures. Receptor activator for nuclear factor κB (RANK) and its ligand, RANKL, are part of an activation pathway for osteoclasts and are thus responsible for bone resorption. Furthermore, RANKL expression is increased in multiple myeloma. In the present study, we investigated the role of single nucleotide polymorphisms (SNPs) in the genes coding for RANK (rs1805034, rs8086340), RANKL (rs7325635, rs7988338), and TACI (rs34562254), a receptor for osteoclast-derived pro-survival factors. The study involved 222 patients and 222 healthy individuals, and the analysis included disease susceptibility, survival, bone lesions, calcium levels, and vascular endothelial growth factor levels. Patients with allele RANK rs1805034 C had higher survival (p = .003). This relationship was especially evident in women (p = .006). Furthermore, allele rs1805034 C was associated with slightly lower median age at diagnosis (64.0 vs. 65.5, p = .008). Allele RANKL rs7325635 A correlated with lower progression-free survival (p = .027), and with lack of early progression (p = .023). Additionally, women with allele rs7325635 G were found to have higher calcium blood concentration (p = .040). Allele TACI rs34562254 A was more common in MM patients in more advanced stages (II and III stage International Staging System) at diagnosis (p = .017), and the SNP showed a slight trend towards association in a multivariate analysis (p = .084). Taken together, our results suggest that RANK rs1805034 and RANKL rs7325635 may have a role in MM development and progression.

show abstract

Whole-Body Imaging of Multiple Myeloma: Diagnostic Criteria

Cited by 2 publications

References 0 publications

Imaging Recommendations for Diagnosis, Staging, and Management of Hematological Malignancies

Imaging Recommendations for Diagnosis, Staging, and Management of Hematological Malignancies

Association of RANK and RANKL gene polymorphism with survival and calcium levels in multiple myeloma

Contact Info

Product

Resources

About